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ABSTRACT
Introduction: The Blood First Assay Screening Trial
revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive
NSCLC for alectinib treatment. To understand the relationship between tissue-based versus blood-based testing,
we retrospectively investigated concordance between
VENTANA ALK (D5F3) CDx immunohistochemistry and the
FoundationACT (FACT; Foundation Medicine, Inc.) plasma
assay, and compared clinical efﬁcacy between phase 3 ALEX
study subpopulations.
Methods: Patients with advanced ALK-positive (by immunohistochemistry) NSCLC were randomized 1:1 to alectinib
600 mg or crizotinib 250 mg, twice daily. Assessable baseline plasma samples were analyzed for ALK positivity by
FACT; positive percent agreement with immunohistochemistry was evaluated. Progression-free survival (PFS), duration of response, and objective response rate were
compared between intention-to-treat (ITT) and biomarkerevaluable populations, and plasma ALK-positive and plasma
ALK-negative subpopulations.
Results: In the ITT population (303 patients; alectinib, 152;
crizotinib, 151), all patients had ALK-positive tumors by
immunohistochemistry. In the biomarker-evaluable population (149 patients; alectinib, 76; crizotinib, 73), 105 had
plasma ALK-positive and 44 had plasma ALK-negative tumors. Positive percent agreement between immunohistochemistry and FACT was 70.5% (105 of 149; 95%
conﬁdence interval: 62.5–77.7). Baseline characteristics

were generally balanced, with some exceptions, notably
tumor burden. Median PFS in plasma ALK-positive and ALKnegative patients was 22.4 months and not estimable with
alectinib and 7.3 months and 12.9 months with crizotinib,
respectively; median duration of response was 25.9 months
and not estimable with alectinib and 5.6 months and 11.5
months with crizotinib, respectively.
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Conclusions: Reasonable concordance between FACT and
immunohistochemistry was observed; both methods are
valuable in identifying ALK-positive patients, separately or
concurrently. Alectinib was found to have superior PFS in
the plasma ALK-positive population, as in the ITT
population.
 2022 The Authors. Published by Elsevier Inc. on behalf of
the International Association for the Study of Lung Cancer.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Introduction
NSCLC treatment paradigms have changed in the past
two decades with the advent of targeted therapies.
Clinical practice guidelines recommend incorporation of
molecular tumor testing into routine practice to guide
clinical care for patients with probable or deﬁnite
adenocarcinoma.1,2 Molecular tumor testing generally
requires a tissue sample to conﬁrm the primary site and
histologic subtype of the cancer.1,2 Nevertheless, owing
to tumor heterogeneity, tissue sampling (an invasive
procedure) in one site may not accurately reﬂect the
comprehensive genomic proﬁle of all lesions.3 Furthermore, adequate tumor tissue may be unavailable due to
inaccessibility of lesions and limitations imposed by
comorbidities associated with NSCLC, such as emphysema or lung ﬁbrosis.4,5 Approximately 26% of repeat
biopsies fail to provide sufﬁcient material for genomic
analysis.6 Consequently, patients with advanced NSCLC
may not receive optimal treatment.7
ALK fusions are the driver genetic alteration in
approximately 5% of NSCLC.8,9 ALK status of a tumor can
be determined in tissue samples using immunohistochemistry (IHC), ﬂuorescence in situ hybridization, polymerase chain reaction, or next-generation sequencing
(NGS).2 The suitability of each assay for identifying patients with ALK-positive NSCLC who may beneﬁt from
ALK inhibitor therapy is determined by the local prescribing information of each drug.
The global, randomized phase 3 ALEX study
(NCT02075840) in patients with treatment-naive
advanced ALK-positive NSCLC revealed signiﬁcantly
improved progression-free survival (PFS) for the ALK
inhibitor alectinib versus crizotinib (stratiﬁed hazard
ratio [HR] 0.43, 95% conﬁdence interval [CI]: 0.32‒0.58)
and established alectinib as a preferred ﬁrst-line treatment option in this setting.1,10–12 The ALK-positive status
of patients in ALEX was prospectively determined by the
VENTANA ALK (D5F3) CDx IHC assay (Ventana Medical

JTO Clinical and Research Reports

Vol. 3 No. 7

Systems, Oro Valley, AZ).10 Plasma samples were taken
at baseline but not tested during screening.
The ongoing Blood First Assay Screening Trial
(BFAST) (NCT03178552) is the ﬁrst study to prospectively assign patients to a treatment based on the
detection of an oncogenic driver using blood-based NGS
as the sole screening method. The aim of BFAST is to
evaluate the relationship between blood-based NGS
detection of actionable mutations in circulating tumor
DNA (ctDNA) and the clinical activity of targeted therapies or immunotherapies in treatment-naive advanced
NSCLC without mandatory tissue sampling.13 BFAST
revealed the clinical applicability of blood-based NGS to
select patients with ALK-positive NSCLC for treatment
with alectinib. In this NGS-selected cohort with ALKpositive NSCLC, alectinib was found to have similar
clinical efﬁcacy to that observed in patients selected
based on IHC tissue testing in the ALEX study. However,
tissue samples were not mandatory in BFAST, so to
further understand the relationship between bloodbased and tumor tissue-based testing for ALK, we conducted an exploratory, retrospective concordance analysis within the ALEX study.
Here, we present the results of the analysis investigating concordance between the VENTANA ALK
(D5F3) IHC CDx tissue assay (used to determine ALK
status in ALEX) and ctDNA testing from the same
patients using the FoundationACT (FACT; Foundation
Medicine Inc., Cambridge, MA) assay. In addition, efﬁcacy (primary end point: investigator-assessed PFS;
secondary end points: investigator-assessed objective
response rate [ORR] and duration of response [DoR])
in different patient subpopulations (intention-to-treat
[ITT] versus biomarker-evaluable population [BEP],
plasma ALK-positive versus plasma ALK-negative population) was determined.

Materials and Methods
ALEX Study Design
Full details of the ALEX study have been published
previously.10 Brieﬂy, patients with stage IIIB or IV ALKpositive NSCLC (determined centrally using VENTANA
ALK [D5F3] CDx IHC tissue assay) were randomized 1:1
to receive alectinib 600 mg twice daily or crizotinib 250
mg twice daily until progressive disease (PD), toxicity,
withdrawal, or death. Patients with asymptomatic brain
or leptomeningeal metastases were eligible for enrolment. Crossover between treatment arms was not
permitted before PD. Further lines of therapy after PD
were at the physician’s discretion and on the basis of
availability.
The study protocol was approved by the Institutional
Review Board or ethics committee at each participating
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center, and the study was conducted in accordance with
the principles of the Declaration of Helsinki, Good Clinical
Practice Guidelines, and local laws. Written informed
consent was obtained from all patients before enrolment.

ALEX Study Assessments
Patients underwent tumor imaging, including brain
scans, at baseline. Tumor response was evaluated every
8 weeks until PD according to Response Evaluation
Criteria in Solid Tumors version 1.1. PFS was deﬁned as
the time from randomization to conﬁrmed PD or death,
whichever occurred ﬁrst. ORR was deﬁned as the percentage of patients with a complete response or partial
response according to Response Evaluation Criteria in
Solid Tumors version 1.1. DoR was deﬁned as the time
from when the criteria for complete response or partial
response were ﬁrst met to the occurrence of a PFS event.
Analyses were based on a clinical cutoff date of
November 30, 2018.
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was not designed for the comparison of diagnostic tests,
no formal statistical testing was planned; the resultant
analyses were therefore not adjusted for multiple
testing. Only plasma samples taken at baseline or on the
day after the start of treatment were included in the
analysis.

Results
Patients

Tissue and plasma samples were tested for ALK
positivity using VENTANA ALK (D5F3) CDx IHC and
FACT assays, respectively. The ITT population included
all patients randomized to study treatment; all patients
had ALK-positive tumors by IHC. The BEP included patients in the ITT population with an available plasma
sample and valid result, taken at baseline or the day after
start of treatment. A valid result was one that passed inprocess quality control metrics criteria, excluding those
with a failed or no result, insufﬁcient input mass (recommended minimum: 30 ng cell-free DNA), or plasma
volume below 2.5 mL. The plasma ALK-positive and
plasma ALK-negative populations comprised all patients
in the BEP whose tumors were ALK positive or ALK
negative, respectively, by FACT. Efﬁcacy results were
compared between the ITT, BEP, plasma ALK-positive,
and plasma ALK-negative populations.
Concordance was assessed between IHC (tissue) and
plasma ALK tests. Because all patients enrolled in the
study (ITT population) had ALK-positive NSCLC by IHC
central analysis per protocol inclusion criteria, only
positive percent agreement (PPA) between FACT and
IHC could be evaluated.

In the ALEX study, 303 patients were randomized to
receive alectinib (n ¼ 152) or crizotinib (n ¼ 151) (ITT
population), of whom 149 patients (49% of ITT population) were included in the BEP (n ¼ 76 alectinib, n ¼
73 crizotinib; Table 1). The plasma ALK-positive population comprised 105 patients (n ¼ 53 alectinib, n ¼ 52
crizotinib); the plasma ALK-negative population included
44 patients (n ¼ 23 alectinib, n ¼ 21 crizotinib; Table 2).
Overall, 154 patients (n ¼ 76 alectinib, n ¼ 78 crizotinib)
were excluded from the BEP (reasons for exclusion: did
not fulﬁll prespeciﬁed sample criteria as deﬁned in the
Concordance Analysis section, n ¼ 127; missing samples,
n ¼ 17; lack of approval from Human Genetics Resources
Administration of China, n ¼ 10) (Supplementary Fig. 1).
Demographic data and baseline characteristics were
generally consistent across each population (ITT, BEP,
plasma ALK positive, and plasma ALK negative) and
balanced between treatment arms, with some exceptions. Of note, the target lesion median sum of longest
diameters was 79.00 mm in the BEP and 68.00 mm in
the ITT population, whereas the proportion of patients
with more than three lesions was 86% and 77%,
respectively, and the percentage of patients with liver
lesions was 34% and 23%, respectively. The proportion
of patients with more than three lesions at baseline was
96.2% and 92.3% in the alectinib and crizotinib arms in
the plasma ALK-positive population and 69.6% and
61.9% in the plasma ALK-negative population, respectively (Table 2). The percentage of patients who presented with liver lesions at baseline was 27.6% and
39.7% in the alectinib and crizotinib arms in the BEP,
19.7% and 26.5% in the ITT population, 35.8% and
46.2% in the plasma ALK-positive population, and 8.7%
and 23.8% in the plasma ALK-negative population,
respectively (Tables 1 and 2).

Statistical Analysis

Concordance Analysis

The Kaplan-Meier method was used to estimate the
median PFS for each treatment arm with 95% CIs. A
stratiﬁed Cox proportional-hazards regression model
was used to estimate the treatment effect, expressed as a
HR together with 95% CI.
The concordance data presented in this manuscript
are from an exploratory, retrospective analysis. As ALEX

Since all patients in the ALEX ITT population were
ALK positive by IHC, only PPA was evaluated. Using ALK
positivity by IHC as the reference standard, PPA of FACT
in plasma was 70.5% (105 of 149 [95% CI: 62.5‒77.7])
and comparable between the alectinib (69.7% [95% CI:
58.1‒79.8]) and crizotinib (71.2% [95% CI: 59.5‒81.2])
arms.

Concordance Analysis
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Table 1. Demographic and Baseline Characteristics of the ITT Population and the BEP
ITT (N ¼ 303)

BEP (n ¼ 149)

Characteristic

Alectinib (n ¼ 152)

Crizotinib (n ¼ 151)

Alectinib (n ¼ 76)

Crizotinib (n ¼ 73)

Age [median], y (range)
<65, n (%)
65, n (%)
Ethnicity, n (%)
Hispanic/Latino
Not Hispanic/Latino
Not stated
Race, n (%)
Asian
Black/African American
Native American
Native Hawaiian
White
Unknown
Smoking status, n (%)
Active smoker
Nonsmoker
Past smoker
ECOG PS, n (%)
0 or 1
2
CNS lesions,a n (%)
No
Yes
Liver lesions, n (%)
Yes
Lesions, n (%)
1–3
>3
Target lesion SLD (median),
mm (range)

58 (25‒88)
115 (75.7)
37 (24.3)

54 (18‒91)
118 (78.1)
33 (21.9)

57 (29‒81)
61 (80.3)
15 (19.7)

54 (18‒91)
59 (80.8)
14 (19.2)

8 (5.3)
138 (90.8)
6 (3.9)

8 (5.3)
136 (90.1)
7 (4.6)

6 (7.9)
68 (89.5)
2 (2.6)

2 (2.7)
67 (91.8)
4 (5.5)

69 (45.4)
0
4 (2.6)
1 (0.7)
76 (50.0)
2 (1.3)

69 (45.7)
4 (2.6)
0
1 (0.7)
75 (49.7)
2 (1.3)

33 (43.4)
0
4 (5.3)
1 (1.3)
37 (48.7)
1 (1.3)

35 (47.9)
1 (1.4)
0
0
36 (49.3)
1 (1.4)

12 (7.9)
91 (59.9)
49 (32.2)

5 (3.3)
97 (64.2)
49 (32.5)

6 (7.9)
48 (63.2)
22 (28.9)

1 (1.4)
44 (60.3)
28 (38.4)

142 (93.4)
10 (6.6)

141 (93.4)
10 (6.6)

66 (86.8)
10 (13.2)

66 (90.4)
7 (9.6)

88 (57.9)
64 (42.1)

93 (61.6)
58 (38.4)

40 (52.6)
36 (47.4)

43 (58.9)
30 (41.1)

30 (19.7)

40 (26.5)

21 (27.6)

29 (39.7)

37 (24.3)
115 (75.7)
72 (10‒206)

34 (22.5)
117 (77.5)
64 (14‒205)

9 (11.8)
67 (88.2)
87 (11‒206)

12 (16.4)
61 (83.6)
74 (15‒205)

a

Assessed by IRC.
BEP, biomarker-evaluable population; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; IRC, independent
review committee; ITT, intention-to-treat; SLD, sum of longest diameter.

Exploratory Analysis: PFS Results
The treatment effect of alectinib versus crizotinib
with respect to PFS in the ITT population and the BEP
was similar (HR ¼ 0.43 [95% CI: 0.32‒0.58] and HR ¼
0.41 [95% CI: 0.27‒0.61], respectively). Median
investigator-assessed PFS in the BEP was 27.9 months
(95% CI: 12.9‒not estimable [NE]) with alectinib versus
9.0 months (95% CI: 7.2‒10.8) with crizotinib (Fig. 1). In
alectinib-treated patients, median PFS was 22.4 months
(95% CI: 12.9‒38.7) versus NE (95% CI: 3.6‒NE) in the
plasma ALK-positive and plasma ALK-negative populations, respectively (Fig. 2). Median PFS with crizotinib
was 7.3 months (95% CI: 6.1‒9.6) versus 12.9 months
(95% CI: 7.5‒18.4) in the plasma ALK-positive and
plasma ALK-negative populations, respectively (Fig. 2).
The PFS HR with alectinib versus crizotinib was 0.37
(95% CI: 0.23‒0.59) in the plasma ALK-positive population and 0.50 (95% CI: 0.22‒1.11) in the plasma ALKnegative population (Fig. 2). The PFS rate in the ITT

population versus the BEP from years 1 to 4 in both
treatment arms is found in Supplementary Figure 2.

Exploratory Analysis: ORR Results
Investigator-assessed ORR by treatment arm was
similar between the ITT population and the BEP. With
alectinib, 82.9% (ITT) and 84.2% (BEP) of patients
achieved an objective response; ORR was 94.3% (95%
CI: 84.3–98.8) in plasma ALK-positive patients and
60.9% (95% CI; 38.5–80.3) in plasma ALK-negative patients (Table 3). In the crizotinib arm, 75.5% (ITT) and
74.0% (BEP) of patients achieved an objective response
(Table 3). The ORR with crizotinib was 80.8% (95% CI:
67.5–90.4) for plasma ALK-positive patients and 57.1%
(95% CI: 34.0–78.2) for plasma ALK-negative patients.

Exploratory Analysis: DoR Results
Median investigator-assessed DoR was similar between the ITT population (alectinib, NE [95% CI: 29.8‒
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Table 2. Demographic and Baseline Characteristics of the Plasma ALK-Positive and Plasma ALK-Negative Populations
Plasma ALK Positive (n ¼ 105)

Plasma ALK Negative (n ¼ 44)

Characteristic

Alectinib (n ¼ 53)

Crizotinib (n ¼ 52)

Alectinib (n ¼ 23)

Crizotinib (n ¼ 21)

Age [median], y (range)
<65, n (%)
65, n (%)
Ethnicity, n (%)
Hispanic or Latino
Not Hispanic or Latino
Not stated
Race, n (%)
Asian
Black or African American
Native American
Native Hawaiian
White
Unknown
Smoking status, n (%)
Active smoker
Nonsmoker
Past smoker
ECOG PS, n (%)
0 or 1
2
CNS lesions,a n (%)
No
Yes
Liver lesions, n (%)
Yes
Lesions, n (%)
1–3
>3
Target lesion SLD (median),
mm (range)

56 (29‒81)
44 (83.0)
9 (17.0)

54 (18‒91)
42 (80.8)
10 (19.2)

58 (42‒74)
17 (73.9)
6 (26.1)

59 (30‒79)
17 (81.0)
4 (19.0)

5 (9.4)
47 (88.7)
1 (1.9)

1 (1.9)
48 (92.3)
3 (5.8)

1 (4.3)
21 (91.3)
1 (4.3)

1 (4.8)
19 (90.5)
1 (4.8)

25 (47.2)
0
3 (5.7)
1 (1.9)
23 (43.4)
1 (1.9)

25 (48.1)
1 (1.9)
0
0
26 (50.0)
0

8 (34.8)
0
1 (4.3)
0
14 (60.9)
0

10 (47.6)
0
0
0
10 (47.6)
1 (4.8)

2 (3.8)
39 (73.6)
12 (22.6)

0
31 (59.6)
21 (40.4)

4 (17.4)
9 (39.1)
10 (43.5)

1 (4.8)
13 (61.9)
7 (33.3)

46 (86.8)
7 (13.2)

46 (88.5)
6 (11.5)

20 (87.0)
3 (13.0)

20 (95.2)
1 (4.8)

30 (56.6)
23 (43.4)

33 (63.5)
19 (36.5)

10 (43.5)
13 (56.5)

10 (47.6)
11 (52.4)

19 (35.8)

24 (46.2)

2 (8.7)

5 (23.8)

2 (3.8)
51 (96.2)
90 (15‒206)

4 (7.7)
48 (92.3)
79 (18‒205)

7 (30.4)
16 (69.6)
57 (11‒198)

8 (38.1)
13 (61.9)
71 (15‒146)

a

Assessed by IRC.
CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; IRC, independent review committee; SLD, sum of longest
diameter.

NE]; crizotinib, 11.1 mo [95% CI: 7.9‒13.0]) and the BEP
(alectinib, 36.9 mo [95% CI: 20.6‒NE]; crizotinib, 7.3 mo
[95% CI: 5.5‒11.1]; Table 4). In the BEP (treatment
arms combined), median DoR was 11.1 months (95% CI:
7.4‒14.8) in the plasma ALK-positive population and NE
(95% CI: 14.5‒NE) in the plasma ALK-negative population (Table 4). Similar results were observed with alectinib in the BEP (Table 4); median DoR was 25.9 months
(95% CI: 11.9‒38.7) in the plasma ALK-positive population and NE (95% CI: NE) in the plasma ALK-negative
population. With crizotinib, median DoR was 5.6 months
(95% CI: 5.5‒9.2) and 11.5 months (95% CI: 6.9‒14.8)
in the plasma ALK-positive and plasma ALK-negative
populations, respectively.
In the ITT population and the BEP, 46.8% and
51.6% of alectinib-treated patients who achieved an
objective response experienced PD or death compared
with 79.8% and 85.2% of crizotinib-treated patients,
respectively (Table 4). In the BEP (treatment arms

combined), 69 of 92 patients (75.0%) with an objective
response progressed or died in the plasma ALK-positive
population compared with 10 of 26 patients (38.5%) in
the plasma ALK-negative population (Table 4). With
alectinib, 32 of 50 patients (64.0%) with an objective
response in the plasma ALK-positive population and 1
of 14 patients (7.1%) with an objective response in the
plasma ALK-negative population progressed or died
(Table 4). With crizotinib, the rate of PD or death was
88.1% in the plasma ALK-positive population and 75.0%
in the plasma ALK-negative population (Table 4).

Discussion
Guidelines recommend testing for several targetable
gene alterations; however, tissue testing for several
biomarkers can be challenging, especially for patients
with limited tissue availability or when repeat biopsies
are not feasible.6,7 Many biomarkers for oncogenic driver
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Figure 1. Kaplan-Meier plot of investigator-assessed PFS in the BEP. BEP, biomarker-evaluable population; CI, conﬁdence
interval; HR, hazard ratio; PFS, progression-free survival.

mutations, some with low prevalence, have been identiﬁed in lung cancer.14 Consequently, extensive molecular
testing for these biomarkers is required to determine the
optimal treatment for each patient.1 Implementing bloodbased NGS analysis would provide a comprehensive, less-

invasive method of analyzing multiple tumor molecular
alterations simultaneously, which may help overcome
some limitations of tissue-based, single-biomarker
testing.2 Moreover, ctDNA analyzed using blood-based
NGS represents the molecular proﬁle of multiple lesion
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Figure 2. Kaplan-Meier plot of investigator-assessed PFS with alectinib versus crizotinib in (A) the plasma ALK-positive and
(B) the plasma ALK-negative population. CI, conﬁdence interval; HR, hazard ratio; PFS, progression-free survival.
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Table 3. Investigator-Assessed Response in the ITT Population, the BEP, and the Plasma ALK-Positive and Plasma ALKNegative Population by Treatment Arm
ITT (N ¼ 303)

BEP (n ¼ 149)

Plasma ALK Positive
(n ¼ 105)

Plasma ALK Negative
(n ¼ 44)

n (%)
95% CI

Alectinib
(n ¼ 152)

Crizotinib
(n ¼ 151)

Alectinib
(n ¼ 76)

Crizotinib
(n ¼ 73)

Alectinib
(n ¼ 53)

Crizotinib
(n ¼ 52)

Alectinib
(n ¼ 23)

Crizotinib
(n ¼ 21)

ORR

126 (82.9)
76.0‒88.5
9 (5.9)
2.7‒10.9
117 (77.0)
69.5‒83.4
9 (5.9)
2.7‒10.9
8 (5.3)
2.3‒10.1
9 (5.9)

114 (75.5)
67.8‒82.1
5 (3.3)
1.1‒7.6
109 (72.2)
64.3‒79.2
24 (15.9)
10.5‒22.7
10 (6.6)
3.2‒11.8
3 (2)

64 (84.2)
74.0‒91.6
5 (6.6)
2.2‒14.7
59 (77.6)
66.6‒86.4
3 (3.9)
0.8‒11.1
5 (6.6)
2.2‒14.7
4 (5.3)

54 (74.0)
62.4‒83.6
0
0.0‒4.9
54 (74.0)
62.4‒83.6
12 (16.4)
8.8‒27.0
5 (6.8)
2.3‒15.3
2 (2.7)

50 (94.3)
84.3‒98.8
3 (5.7)
1.2‒15.7
47 (88.7)
77.0‒95.7
1 (1.9)
0.1‒10.1
0
0.0‒6.7
2 (3.8)

42 (80.8)
67.5‒90.4
0
0.0‒6.9
42 (80.8)
67.5‒90.4
7 (13.5)
5.6‒25.8
2 (3.8)
0.5‒13.2
1 (1.9)

14 (60.9)
38.5‒80.3
2 (8.7)
1.1‒28.0
12 (52.2)
30.6‒73.2
2 (8.7)
1.1‒28.0
5 (21.7)
7.5‒43.7
2 (8.7)

12 (57.1)
34.0‒78.2
0
0‒16.1
12 (57.1)
34.0‒78.2
5 (23.8)
8.2‒47.2
3 (14.3)
3.1‒36.3
1 (4.8)

CR
PR
Stable disease
PD
Missing or unassessable

BEP, biomarker-evaluable population; CI, conﬁdence interval; CR, complete response; ITT, intention to treat; ORR, objective response rate; PD, progressive
disease; PR, partial response.

sites and may better detect tumor heterogeneity than
localized, tissue-based testing from a single sample.3
Initial results from the ALK-positive cohort of BFAST
revealed the clinical utility of blood-based NGS in a tissueagnostic patient population selected by blood-based
NGS.13 The primary end point of the ALK-positive cohort
(conﬁrmed ORR by investigator, 87.4%) was achieved; an
independent review facility-conﬁrmed ORR of 92.0% was
reported.13 These data are consistent with the investigatorassessed ORR of 82.9% observed with alectinib in ALEX15
and reveal the clinical utility of blood-based NGS as a
method to inform clinical decision-making in ALK-positive
NSCLC. However, BFAST was not designed to assess
concordance between IHC and NGS testing.
The ALEX concordance analysis presented here is
retrospective and exploratory, using data from the BEP,
which comprised approximately 50% of the ITT population. These results, consistent with those from BFAST,
suggest that tissue- and blood-based detection of ALK
fusions are viable and complementary options to select
patients for treatment with alectinib. However, as can be
observed from the results, plasma testing may fail to
detect ALK-positive tumors, because this method relies
heavily on tumors shedding ctDNA into the blood
stream. We found a PPA of 70.5% between the VENTANA IHC and FACT plasma assays (as all patients had
ALK-positive tumors by IHC, per study protocol, only
PPA could be analyzed). This suggests that in the event
of a negative ALK result using plasma testing, reﬂex
testing using a tissue test should be considered where
feasible as a response was observed in the plasma ALKnegative population, as outlined in the technical information for FoundationOne Liquid CDx, the Food and
Drug Administration–approved successor to FACT.16

The PPA result may have been affected by the comparison of two different analytes, protein and ctDNA
(IHC versus blood-based NGS), as the recent concordance analysis between ﬂuorescence in situ hybridization and IHC, where both assays used tumor samples
from ALEX patients, reported a PPA of 83.9%.17 In
addition, other factors, such as the kinetics of the targeted analyte or nature of the genetic alteration may
have played a role. Differences in interpretation of results may also lead to discordance, especially for samples
close to the assay limit of detection. Detection of oncogenic drivers in plasma, such as ALK rearrangements or
EGFR point mutations, may be affected by the level of
ctDNA shedding from the tumor or background
cfDNA.18,19 Similar to our observations, a PPA of 79%
and 68%, respectively, was found in a comparison of
blood- and tissue-based testing for the detection of
Ex19del and L858R EGFR mutations in the phase 3 osimertinib trial, FLAURA.20
An important advantage of NGS assays is that multiple gene alterations can be assessed simultaneously.2
With the increasing number of Food and Drug
Administration–approved targeted therapies, an assay
that can detect targetable alterations in multiple genes is
preferred over conducting multiple separate tests for
individual gene alterations, as the latter can deplete
tissue obtained from biopsies, meaning rare biomarkers
may not be tested for and patients may not receive
targeted therapy.2
In this analysis, investigator-assessed ORR was
similar between the alectinib and crizotinib arms in the
ITT population. However, for both treatment arms, ORR
appeared to be numerically higher in the plasma ALKpositive population, whereas PFS appeared to be
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Table 4. Investigator-Assessed DoR in the ITT Population,
the BEP, and the Plasma ALK-Positive and Plasma ALKNegative Populations
ITT (N ¼ 303)
DoR

Alectinib
(n ¼ 152)

Crizotinib
(n ¼ 151)

Patients analyzed, n
Patients with event,a n (%)
DoR (median), mo (95% CI)

126
59 (46.8)
NE (29.8‒NE)

114
91 (79.8)
11.1 (7.9‒13.0)

BEP (n ¼ 149)

Patients analyzed, n
Patients with event,a n (%)
DoR (median), mo (95% CI)

Alectinib
(n ¼ 76)

Crizotinib
(n ¼ 73)

64
33 (51.6)
36.9 (20.6‒NE)

54
46 (85.2)
7.3 (5.5‒11.1)

BEP
Alectinib and crizotinib arms
combined (n ¼ 149)

Patients analyzed, n
Patients with event,a n (%)
DoR (median), mo (95% CI)

Plasma ALK
positive
(n ¼ 105)

Plasma ALK
negative
(n ¼ 44)

92
69 (75.0)
11.1 (7.4‒14.8)

26
10 (38.5)
NE (14.5‒NE)

BEP
Alectinib arm only (n ¼ 76)

Patients analyzed, n
Patients with event,a n (%)
DoR (median), mo (95% CI)

Plasma ALK
positive
(n ¼ 53)

Plasma ALK
negative
(n ¼ 23)

50
32 (64.0)
25.9 (11.9‒38.7)

14
1 (7.1)
NE (NE)

BEP
Crizotinib arm only (n ¼ 73)

Patients analyzed, n
Patients with event,a n (%)
DoR (median), mo (95% CI)

Plasma ALK
positive
(n ¼ 52)

Plasma ALK
negative
(n ¼ 21)

42
37 (88.1)
5.6 (5.5‒9.2)

12
9 (75.0)
11.5 (6.9‒14.8)

a

Event deﬁned as PD or death.
BEP, biomarker-evaluable population; CI, conﬁdence interval; DoR, duration
of response; ITT, intention to treat; NE, not estimable; PD, progressive
disease.

numerically longer in the plasma ALK-negative population. Similarly, with alectinib, DoR appeared to be
numerically longer in the plasma ALK-negative versus
the plasma ALK-positive population. These ﬁndings may
be explained by the disparity in tumor burden and
visceral involvement (sum of longest diameters, lesions,
and liver lesions) found in plasma ALK-positive
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compared with plasma ALK-negative patients, likely
representing a population with worse overall prognosis.
Reasons for this potential disparity in PFS and DoR in
plasma ALK-positive versus plasma ALK-negative patients are unclear but could be due to the small patient
numbers in each subgroup. It has been suggested that
increased ctDNA shed identiﬁes a subset of patients with
worse prognosis.21 Larger data sets are required to
conﬁrm this observation.
In the phase 3 FLAURA trial, similar to the results
presented here, the absence of an EGFR mutation in
plasma was associated with prolonged PFS, potentially
owing to lower tumor burden in these patients
compared with those harboring a detectable EGFR mutation in plasma.20 It is worth noting that some patients
who may derive beneﬁt from targeted treatments such
as ALK or EGFR inhibitors may not be identiﬁed using a
blood-based assay, so a tissue sample would be required
for reﬂex testing, as found in this analysis. However,
because all patients included in ALEX were ALK positive
by IHC, this concordance analysis does not include patients who were ALK negative by IHC but ALK positive by
blood-based NGS.
A limitation of this analysis is its exploratory, retrospective nature. The ALEX study was not designed to
compare diagnostic tests; therefore, no formal statistical
testing was planned. Furthermore, some populations
contained a limited sample size because the ALEX study
was not designed with these subpopulations in mind.
Optimal plasma volumes were not collected for all patients, and samples with lower than required volumes
were not selected for analysis, as deﬁned in the
Concordance Analysis section.
In conclusion, in this analysis, the blood-based NGS
assay FACT revealed a 70.5% PPA compared against
protein-based VENTANA ALK (D5F3) CDx IHC, comparable with other ctDNA genotyping assays. When taken
together with results from BFAST, this analysis indicates
that blood-based NGS is an additional, important option
to test patients for targetable biomarkers and is a valuable diagnostic tool to direct optimal treatment choice
for patients with advanced ALK-positive NSCLC.16
Finally, this analysis reveals that plasma ALK-positive
patients can derive clinical beneﬁt from ALK inhibitors
and that in this patient population, as in the ITT population, alectinib demonstrated superior PFS compared
with crizotinib.
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